Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine.
OBJECTIVE
To describe the incidence, clinical characteristics and dose relationship of dideoxyinosine (ddI)-associated pancreatitis.


METHODS
Patients enrolled in a Phase I dose escalation trial of ddI [AIDS Clinical Trials Group (ACTG) 064] were evaluated for signs and symptoms of pancreatic dysfunction.


METHODS
Two ACTG sites.


METHODS
Forty-four patients with AIDS or AIDS-related complex (ARC) and a CD4 cell count less than or equal to 400 x 10(6)/l.


METHODS
Seven patients developed pancreatitis that lasted from 1 to 7 weeks and varied in severity from mild to life-threatening. Seven other patients had evidence of hyperamylasemia or hypertriglyceridemia. Six patients who developed pancreatitis were able to tolerate rechallenge with lower doses of ddI.


RESULTS
Development of pancreatitis correlated with cumulative dose of ddI but not with stage of disease or concomitant medications. Cumulative dose was not significantly associated with development of hyperamylasemia or hypertriglyceridemia in patients without clinical pancreatitis.


CONCLUSIONS
The development of pancreatitis in AIDS or ARC patients receiving ddI varies in severity and time course and is associated with cumulative dose. Patients who develop pancreatitis may be able to tolerate therapy with a lower dose after resolution of their symptoms. Patients receiving ddI require careful monitoring for the development of this complication.
Seidlin
M
M
Department of Medicine, New York University Medical Center, New York.
Lambert
J S
JS
Dolin
R
R
Valentine
F T
FT
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D016049:Didanosine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D010182:Pancreatic Diseases / Q000139:chemically induced* / Q000503:physiopathology; D010195:Pancreatitis / Q000139:chemically induced*
D016049:Didanosine